Conditional recommendation:

Consider baricitinib for people 2 years and over in hospital with COVID-19 who:

  • need supplemental oxygen for COVID-19, and
  • are having or have completed a course of corticosteroids such as dexamethasone, unless they cannot have corticosteroids, and
  • have no evidence of infection (other than SARS-CoV-2) that might be worsened by baricitinib.

 

In March 2023, this was an off-label use of baricitinib. See NICE's information on prescribing medicines

Baricitinib may be considered in people who meet the above criteria, and who cannot have tocilizumab. When there is clinical deterioration despite treatment with tocilizumab, it may be appropriate to add baricitinib. 

Baricitinib is contraindicated in pregnancy and breastfeeding. The Royal College of Obstetricians and Gynaecologists has produced guidance on managing coronavirus infection in pregnancy.

 

Adapted from NICE COVID-19 rapid guideline: Managing COVID-19 - Therapeutics for COVID-19